TPBG

Summary

TPBG (trophoblast glycoprotein, HGNC:12004) is a protein-coding gene on chromosome 6q14.1, encoding Trophoblast glycoprotein (Q13641). May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization.

This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. The encoded protein is an oncofetal antigen that is specific to trophoblast cells. In adults this protein is highly expressed in many tumor cells and is associated with poor clinical outcome in numerous cancers. Alternate splicing in the 5’ UTR results in multiple transcript variants that encode the same protein.

Source: NCBI Gene 7162 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 63 total
• Druggable target: yes
• MANE Select transcript: NM_001376922

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12004
Approved symbol	TPBG
Name	trophoblast glycoprotein
Location	6q14.1
Locus type	gene with protein product
Status	Approved
Aliases	5T4-AG, 5T4
Ensembl gene	ENSG00000146242
Ensembl biotype	protein_coding
OMIM	190920
Entrez	7162

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000369750, ENST00000535040, ENST00000543496, ENST00000885042, ENST00000885043, ENST00000885044, ENST00000930942, ENST00000930943

RefSeq mRNA: 3 — MANE Select: NM_001376922 NM_001166392, NM_001376922, NM_006670

CCDS: CCDS4995

Canonical transcript exons

ENST00000369750 — 2 exons

Exon	Start	End
ENSE00001450788	82364623	82367420
ENSE00001450789	82363817	82363908

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 96.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 40.1880 / max 1019.7658, expressed in 1511 samples.

FANTOM5 promoters (22 alternative TSS)

Promoter ID	TPM avg	Samples expressed
68734	11.9662	1361
68733	11.9299	1423
68739	2.3872	980
68730	1.7628	609
68732	1.2881	571
68719	1.2411	105
68744	1.1750	593
68731	1.0885	251
68743	0.9140	395
68724	0.8909	125

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus muscularis layer	UBERON:0035833	96.90	gold quality
lower esophagus	UBERON:0013473	96.87	gold quality
stromal cell of endometrium	CL:0002255	94.34	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.20	gold quality
esophagus	UBERON:0001043	92.20	gold quality
mucosa of stomach	UBERON:0001199	89.62	gold quality
urinary bladder	UBERON:0001255	88.58	gold quality
esophagus mucosa	UBERON:0002469	88.45	gold quality
lower esophagus mucosa	UBERON:0035834	88.18	gold quality
descending thoracic aorta	UBERON:0002345	88.10	gold quality
endocervix	UBERON:0000458	87.67	gold quality
endometrium	UBERON:0001295	87.40	gold quality
ascending aorta	UBERON:0001496	87.38	gold quality
thoracic aorta	UBERON:0001515	87.37	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.29	gold quality
vagina	UBERON:0000996	85.97	gold quality
minor salivary gland	UBERON:0001830	85.93	gold quality
left uterine tube	UBERON:0001303	85.62	gold quality
omental fat pad	UBERON:0010414	85.45	gold quality
saliva-secreting gland	UBERON:0001044	85.16	gold quality
ectocervix	UBERON:0012249	84.85	gold quality
putamen	UBERON:0001874	84.76	gold quality
uterine cervix	UBERON:0000002	84.43	gold quality
body of uterus	UBERON:0009853	83.35	gold quality
placenta	UBERON:0001987	83.25	gold quality
skin of abdomen	UBERON:0001416	83.17	gold quality
thoracic mammary gland	UBERON:0005200	83.10	gold quality
left lobe of thyroid gland	UBERON:0001120	83.07	gold quality
adipose tissue	UBERON:0001013	83.04	gold quality
zone of skin	UBERON:0000014	82.98	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-10485	yes	587.19
E-HCAD-5	yes	348.83
E-GEOD-75140	yes	181.22
E-ANND-3	yes	3.65

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

104 targeting TPBG, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489

Literature-anchored findings (GeneRIF, showing 16)

• Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen (PMID:11903056)
• Results sugest that 5T4 is a transient marker of human embryonic stem cell differentiation & that 5T4 phenotype, colony seeding density and culture conditions influence the maintenance of pluripotent hES cells and their differentiation to neural lineages. (PMID:16616918)
• there is a repertoire of CD8 T cell recognition of 5T4 in normal human donors and some candidate HLA-A*0201 epitopes have been identified (PMID:16646078)
• the mRNA expression of trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia. (PMID:17978129)
• 5T4-based cancer vaccine: cytotoxic T lymphocyte epitopes identified in Trovax-vaccinated colorectal cancer patients (PMID:18567615)
• colorectal cancer patients who had preexisting cell proliferative responses to 5T4 were longer-term survivors (PMID:18833005)
• 5T4 is a potential new antigen for targeted therapies such as immunotherapy in MPM, as it is overexpressed on mesothelioma cells and recognised by 5T4-specific cytotoxic T-cells. (PMID:22498111)
• The surface expression of 5T4 marks the use of the CXCR4 rather than the CXCR7 receptor, with distinct consequences for CXCL12 exposure. (PMID:22956548)
• Tyrosine 325 plus the leucine-rich repeat 1 surface centered on a second exposed aromatic residue, phenylalanine 97, are essential for inhibition of Wnt/beta-catenin signaling. (PMID:24582434)
• 5T4 expression is mechanistically associated with the directional movement of cells through epithelial mesenchymal transition, facilitation of CXCL12/CXCR4 chemotaxis, blocking of canonical Wnt/beta-catenin while favouring non-canonical pathway signalling (PMID:25066861)
• In conclusion, the present study provided evidence that TPBG is involved in PDAC metastasis, and that TPBG and its associated signaling pathways may be a suitable target for pancreatic ductal adenocarcinoma therapy. (PMID:25738465)
• Collectively, these findings demonstrate that an anti-5T4 antibody-drug conjugate reduces the fraction of cancer stem cells (CSC), and prevents local recurrence and suggest a novel therapeutic approach for patients with head and neck squamous cell carcinoma. (PMID:27780858)
• We obtained GWS evidence (P < 2.7 x 10(-6)) for gene-based association in the total sample with a novel locus, TPBG (P = 1.8 x 10(-6)). (PMID:28183528)
• In extravillous trophoblasts, 5T4 may function in epithelial-to-mesenchymal transition during placentation. The role of syncytiotrophoblast 5T4 is unknown, but its abundance in shed syncytial vesicles may signify route of sensitization of the maternal immune system. (PMID:28481180)
• TPBG orchestrates the migratory and angiogenic activities of pericytes through the activation of the CXCL12/CXCR7/pERK axis. (PMID:31018661)
• LINC00342 induces metastasis of lung adenocarcinoma by targeting miR-15b/TPBG. (PMID:35452205)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tpbg	ENSDARG00000037186
mus_musculus	Tpbg	ENSMUSG00000035274
rattus_norvegicus	Tpbg	ENSRNOG00000010694
drosophila_melanogaster	CG7702	FBGN0038638
caenorhabditis_elegans	iglr-3	WBGENE00021353

Protein

Protein identifiers

Trophoblast glycoprotein — Q13641 (reviewed: Q13641)

Alternative names: 5T4 oncofetal antigen, 5T4 oncofetal trophoblast glycoprotein, M6P1, Wnt-activated inhibitory factor 1

All UniProt accessions (1): Q13641

UniProt curated annotations — full annotation on UniProt →

Function. May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization.

Subcellular location. Cell membrane.

Tissue specificity. Expressed by all types of trophoblasts as early as 9 weeks of development. Specific for trophoblastic cells except for amniotic epithelium. In adult tissues, the expression is limited to a few epithelial cell types but is found on a variety of carcinoma.

Post-translational modifications. Highly glycosylated.

Domain organisation. The C-terminus of LRR N-terminal cap (LRRNT) and LRR 1 are essential for the inhibition of the Wnt signaling pathway.

Miscellaneous. Antigen 5T4 is overexpressed by a wide spectrum of cancers, including colorectal, ovarian and gastric, but with a limited normal tissue expression. Could be used for tumor immunotherapy. Reduction of TPBG levels by siRNA significantly enhanced the beta-catenin/TCF transcription-based reporter pBAR activation in response to Wnt stimulation.

RefSeq proteins (3): NP_001159864, NP_001363851, NP_006661 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR052286	Wnt_signaling_inhibitor	Family

Pfam: PF01462, PF01463, PF13855

UniProt features (60 total): strand 16, helix 11, repeat 7, turn 6, mutagenesis site 5, disulfide bond 4, glycosylation site 3, domain 2, topological domain 2, signal peptide 1, chain 1, modified residue 1, transmembrane region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
4CNM	X-RAY DIFFRACTION	1.75
4CNC	X-RAY DIFFRACTION	1.77
6HBY	X-RAY DIFFRACTION	1.95

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13641-F1	82.94	0.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 418

Disulfide bonds (4): 62–68, 66–77, 298–323, 300–344

Glycosylation sites (3): 81, 124, 275

Mutagenesis-validated functional residues (5):

Position	Phenotype
76	strongly reduces wnt inhibitory function.
97	strongly reduces wnt inhibitory function.
124	impaired trafficking to the cell surface.
214	impaired trafficking to the cell surface.
325	reduces wnt inhibitory function.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 321 (showing top): GOBP_DENDRITE_DEVELOPMENT, RNGTGGGC_UNKNOWN, BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_COGNITION, GGTGTGT_MIR329, GOBP_BEHAVIOR, GOBP_CELL_CHEMOTAXIS, GOBP_SYNAPSE_ASSEMBLY, SP3_Q3, GOBP_ASSOCIATIVE_LEARNING, KOINUMA_COLON_CANCER_MSI_UP, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN

GO Biological Process (13): cell adhesion (GO:0007155), negative regulation of cell population proliferation (GO:0008285), olfactory learning (GO:0008355), positive regulation of chemotaxis (GO:0050921), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), synaptic transmission, GABAergic (GO:0051932), positive regulation of synapse assembly (GO:0051965), cell chemotaxis (GO:0060326), positive regulation of ERK1 and ERK2 cascade (GO:0070374), protein localization to plasma membrane (GO:0072659), negative regulation of canonical Wnt signaling pathway (GO:0090090), mesenchymal cell migration (GO:0090497), dendrite arborization (GO:0140059)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): endoplasmic reticulum (GO:0005783), plasma membrane (GO:0005886), cell surface (GO:0009986), dendrite (GO:0030425), axon terminus (GO:0043679), cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
chemotaxis	2
cellular process	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
associative learning	1
olfactory behavior	1
positive regulation of response to external stimulus	1
positive regulation of locomotion	1
regulation of chemotaxis	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
positive regulation of intracellular signal transduction	1
chemical synaptic transmission	1
synapse assembly	1
positive regulation of nervous system development	1
regulation of synapse assembly	1
positive regulation of cell junction assembly	1
cell migration	1
cellular response to chemical stimulus	1
positive regulation of MAPK cascade	1
ERK1 and ERK2 cascade	1
regulation of ERK1 and ERK2 cascade	1
protein localization to membrane	1
protein localization to cell periphery	1
negative regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
ameboidal-type cell migration	1
dendrite morphogenesis	1
neuron projection arborization	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
neuron projection	1
dendritic tree	1

Protein interactions and networks

STRING

1122 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TPBG	TRABD2A	Q86V40	507
TPBG	CTAG1A	P78358	505
TPBG	MUC1	P13931	501
TPBG	MAGEC1	O60732	489
TPBG	LRP5	O75197	487
TPBG	MAGEC2	Q9UBF1	441
TPBG	FOLH1	Q04609	428
TPBG	ADAMTSL5	Q6ZMM2	419
TPBG	SERPINB9	P50453	416
TPBG	SRPX	P78539	407
TPBG	CEACAM5	P06731	403
TPBG	MSLN	Q13421	401
TPBG	OPLAH	O14841	387
TPBG	P4HA1	P13674	377
TPBG	STEAP1	Q9UHE8	371

IntAct

21 interactions, top by confidence:

A	B	Type	Score
KLRG2	GLRX3	psi-mi:“MI:0914”(association)	0.640
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
FAM241A	NRP1	psi-mi:“MI:0914”(association)	0.530
FAM241A	SPTLC2	psi-mi:“MI:0914”(association)	0.530
GIPC1	TPBG	psi-mi:“MI:0403”(colocalization)	0.440
GIPC1	TPBG	psi-mi:“MI:0915”(physical association)	0.440
TPBG	GIPC1	psi-mi:“MI:0915”(physical association)	0.440
	SHTN1	psi-mi:“MI:0914”(association)	0.350
	TMEM223	psi-mi:“MI:0914”(association)	0.350
	VPS37C	psi-mi:“MI:0914”(association)	0.350
PODXL2	GALNT2	psi-mi:“MI:0914”(association)	0.350
CD68	TCAF2	psi-mi:“MI:0914”(association)	0.350
CLGN	TMEM131L	psi-mi:“MI:0914”(association)	0.350
CFTR	UBA6	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (39): TPBG (Affinity Capture-MS), TPBG (Affinity Capture-MS), TPBG (Affinity Capture-MS), GIPC1 (Two-hybrid), GIPC1 (Affinity Capture-Western), TPBG (Two-hybrid), TPBG (Affinity Capture-MS), TPBG (Affinity Capture-MS), TPBG (Affinity Capture-MS), TPBG (Positive Genetic), TPBG (Affinity Capture-MS), TPBG (Affinity Capture-MS), TPBG (Affinity Capture-MS), TPBG (Affinity Capture-MS), TPBG (Affinity Capture-MS)

ESM2 similar proteins: A1A4H9, A2ARI4, A2VDH3, A6H793, D4A6D8, E9Q7T7, F1MLX5, F1MT22, O75325, P59034, P59035, Q13641, Q149C3, Q3URE9, Q3UVD5, Q3UY51, Q4KLL3, Q4R8Y9, Q50LG9, Q5M8M9, Q5PQV5, Q5R6B1, Q5RDJ4, Q5VT99, Q6GQU6, Q6UY18, Q6ZSA7, Q7M6Z0, Q7TQ62, Q80WD1, Q86UE6, Q86UN2, Q86UN3, Q86WK6, Q8BHA1, Q8K0S5, Q8K377, Q8N7C0, Q91ZV8, Q96FE5

Diamond homologs: A2VDH3, O88280, Q13641, Q3UY51, Q4KLL3, Q5VT99, Q6ZSA7, A2AJ76, A4IFA6, A6NJW4, A8WHP9, O14498, P14770, P59034, P59035, Q15109, Q28173, Q4R8Y9, Q5NVQ6, Q5RKR3, Q62151, Q63495, Q6GU68, Q6UXK2, Q6WRH9, Q96RW7, A2ARI4, A3KNN3, A4IIW9, A6H789, A6H793, D4AC13, E7FE13, E9Q7T7, F1MLX5, G3XA59, G5EFX6, O02833, O75093, O75094

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

413 predictions. Top by Δscore:

Variant	Effect	Δscore
6:82363535:CCAAG:C	donor_loss	0.9800
6:82363536:CAAG:C	donor_loss	0.9800
6:82363537:AAG:A	donor_loss	0.9800
6:82363979:TGGA:T	donor_gain	0.9600
6:82363980:GGAG:G	donor_gain	0.9600
6:82363549:G:GG	donor_gain	0.9500
6:82363548:A:AG	donor_gain	0.9400
6:82364278:G:GT	donor_gain	0.9400
6:82364618:CCCA:C	acceptor_loss	0.9300
6:82364619:CCA:C	acceptor_loss	0.9300
6:82364620:CA:C	acceptor_loss	0.9300
6:82364621:AGGTC:A	acceptor_loss	0.9300
6:82364622:G:C	acceptor_loss	0.9300
6:82363907:AGGTG:A	donor_loss	0.9200
6:82363908:GGT:G	donor_loss	0.9200
6:82363909:GTG:G	donor_loss	0.9200
6:82363910:T:G	donor_loss	0.9200
6:82364733:GCC:G	donor_gain	0.9200
6:82364279:A:T	donor_gain	0.9000
6:82364621:A:AG	acceptor_gain	0.9000
6:82364622:G:GG	acceptor_gain	0.9000
6:82363911:GA:G	donor_loss	0.8900
6:82364689:G:GT	donor_gain	0.8800
6:82363982:A:T	donor_gain	0.8700
6:82364283:A:T	donor_gain	0.8700
6:82364293:G:GT	donor_gain	0.8700
6:82365092:C:A	acceptor_gain	0.8600
6:82363906:GAG:G	donor_gain	0.8500
6:82363906:G:GT	donor_gain	0.8400
6:82364309:G:T	donor_gain	0.8400

AlphaMissense

2712 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:82366039:G:C	G360R	0.999
6:82366060:G:C	G367R	0.999
6:82366061:G:A	G367D	0.999
6:82366040:G:A	G360D	0.998
6:82366069:T:C	F370L	0.998
6:82366071:C:A	F370L	0.998
6:82366071:C:G	F370L	0.998
6:82366132:G:C	A391P	0.998
6:82366135:T:C	C392R	0.998
6:82365185:T:A	V75D	0.997
6:82365190:T:A	C77S	0.997
6:82365191:G:C	C77S	0.997
6:82366052:C:A	A364D	0.997
6:82366055:T:C	L365P	0.997
6:82366058:T:A	I366K	0.997
6:82366091:A:T	N377I	0.997
6:82366107:A:C	K382N	0.997
6:82366107:A:T	K382N	0.997
6:82366073:T:C	L371P	0.996
6:82366093:C:A	R378S	0.996
6:82366094:G:C	R378P	0.996
6:82366103:T:A	I381K	0.996
6:82365190:T:C	C77R	0.995
6:82365293:T:G	F111C	0.995
6:82365847:T:A	W296R	0.995
6:82365847:T:C	W296R	0.995
6:82365854:G:A	C298Y	0.995
6:82366079:T:A	V373D	0.995
6:82366084:T:G	Y375D	0.995
6:82366092:C:A	N377K	0.995

dbSNP variants (sampled 300 via entrez): RS1000089480 (6:82367510 T>C), RS1000101329 (6:82361739 T>G), RS1000917225 (6:82363803 C>A,T), RS1000933353 (6:82364478 G>A), RS1001920819 (6:82364754 G>A,C,T), RS1002881506 (6:82365910 G>A), RS1003065053 (6:82364029 G>A,T), RS1003369431 (6:82363473 A>C), RS1003982702 (6:82364262 C>A), RS1004020 (6:82364248 G>A), RS1004638213 (6:82364760 G>A,C), RS1005393983 (6:82365536 A>C,G), RS1005993990 (6:82366911 A>T), RS1006279505 (6:82363988 G>A), RS1006295314 (6:82367098 T>G)

Disease associations

OMIM: gene MIM:190920 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012291_7	Schizophrenia, bipolar disorder or recurrent major depressive disorder	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004952	disease recurrence

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712934 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Tumour-associated antigens

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
naptumomab estafenatox	Binding	9.0	pKd
anatumomab mafenatox	Binding	8.92	pKd

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	7
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	4
trichostatin A	affects cotreatment, decreases expression	3
Aflatoxin B1	affects expression, decreases methylation, increases expression	3
mercuric bromide	affects cotreatment, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment, increases expression	2
Calcitriol	increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tretinoin	decreases expression, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
FR900359	increases phosphorylation	1
methylmercuric chloride	decreases expression	1
afimoxifene	decreases reaction, increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	increases expression	1
cupric chloride	increases expression	1
nickel sulfate	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
S 1 (combination)	decreases response to substance	1
cylindrospermopsin	decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
eprenetapopt	affects expression, affects reaction	1
LDN 193189	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1A0	Abcam MCF-7 TPBG KO	Cancer cell line	Female
CVCL_E6SA	Genomeditech CHO-K1 H_TPBG	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.